FI3850946T3 - Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni - Google Patents

Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni Download PDF

Info

Publication number
FI3850946T3
FI3850946T3 FIEP20215046.2T FI20215046T FI3850946T3 FI 3850946 T3 FI3850946 T3 FI 3850946T3 FI 20215046 T FI20215046 T FI 20215046T FI 3850946 T3 FI3850946 T3 FI 3850946T3
Authority
FI
Finland
Prior art keywords
rodent
gene
human
polypeptide
humanized
Prior art date
Application number
FIEP20215046.2T
Other languages
English (en)
Finnish (fi)
Inventor
Cagan Gurer
Ella Ioffe
Alexander Mujica
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54979926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3850946(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of FI3850946T3 publication Critical patent/FI3850946T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
FIEP20215046.2T 2014-12-05 2015-11-25 Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni FI3850946T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462087992P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
FI3850946T3 true FI3850946T3 (fi) 2023-12-28

Family

ID=54979926

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20215046.2T FI3850946T3 (fi) 2014-12-05 2015-11-25 Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni

Country Status (29)

Country Link
US (5) US20160345549A1 (enExample)
EP (4) EP4296278A3 (enExample)
JP (2) JP6730277B2 (enExample)
KR (3) KR102313073B1 (enExample)
CN (2) CN107205368B (enExample)
AR (1) AR102888A1 (enExample)
AU (2) AU2015355328B2 (enExample)
BR (1) BR112017010490A2 (enExample)
CA (1) CA2967834C (enExample)
CY (2) CY1121547T1 (enExample)
DK (3) DK3086637T3 (enExample)
ES (3) ES2716735T3 (enExample)
FI (1) FI3850946T3 (enExample)
HR (3) HRP20190634T1 (enExample)
HU (3) HUE043132T2 (enExample)
IL (2) IL286403B2 (enExample)
LT (3) LT3466255T (enExample)
MX (1) MX2017007293A (enExample)
NZ (2) NZ731471A (enExample)
PL (3) PL3466255T3 (enExample)
PT (3) PT3466255T (enExample)
RS (3) RS58536B1 (enExample)
RU (1) RU2728412C2 (enExample)
SG (2) SG11201703463WA (enExample)
SI (3) SI3850946T1 (enExample)
SM (3) SMT201900178T1 (enExample)
TR (1) TR201903891T4 (enExample)
TW (1) TWI681053B (enExample)
WO (1) WO2016089692A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3850946T3 (fi) 2014-12-05 2023-12-28 Regeneron Pharma Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni
EP3808775B1 (en) 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
WO2016154299A1 (en) * 2015-03-24 2016-09-29 The Trustees Of Columbia University In The City Of New York Genetic modification of pigs for xenotransplantation
EP3689139B1 (en) 2015-05-29 2025-01-01 Regeneron Pharmaceuticals, Inc. Rodent cells having a disruption in a c9orf72 locus
KR102454546B1 (ko) 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
EP3411392B1 (en) 2016-02-04 2021-12-29 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
EP3895529B1 (en) 2016-02-29 2026-04-29 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
JP7134944B2 (ja) * 2016-08-11 2022-09-12 ザ ジャクソン ラボラトリー 遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物
WO2018041121A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN107815465B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
EP3518667B1 (en) * 2016-09-30 2024-10-30 Regeneron Pharmaceuticals, Inc. Rodents having a hexanucleotide repeat expansion in a c9orf72 locus
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
CN108588126B (zh) * 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
WO2018177441A1 (en) * 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
WO2018227286A1 (en) * 2017-06-12 2018-12-20 Sinai Health System Allograft tolerance without the need for systemic immune suppression
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
IL274740B2 (en) * 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
WO2019190990A1 (en) * 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12622932B2 (en) 2018-12-13 2026-05-12 Sinai Health System Immunomodulatory cells and uses thereof
US11690362B2 (en) 2018-12-20 2023-07-04 Regeneran Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
WO2020147829A1 (zh) * 2019-01-17 2020-07-23 北京百奥赛图基因生物技术有限公司 人源化转基因动物
US20220312749A1 (en) * 2019-08-09 2022-10-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il2ra
CN112553252B (zh) * 2019-09-06 2022-04-29 百奥赛图(北京)医药科技股份有限公司 Tnfr2基因人源化的非人动物的构建方法和应用
WO2021136537A1 (en) * 2019-12-31 2021-07-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα/CD47
CN112080522A (zh) * 2020-09-15 2020-12-15 广东药康生物科技有限公司 一种cd47人源化小鼠模型的构建方法
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
WO2023046061A1 (en) * 2021-09-24 2023-03-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric trop2
AU2023310163A1 (en) 2022-07-19 2025-01-16 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
WO2025171307A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2545166A1 (en) * 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Humanized anti-cd47 antibody
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
ES2378407T3 (es) * 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
CN101668387A (zh) 2008-09-02 2010-03-10 鸿富锦精密工业（深圳）有限公司 印刷电路板
JP5073836B2 (ja) * 2009-01-16 2012-11-14 公益財団法人実験動物中央研究所 ヒト肝細胞が移植されたマウス
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
US8758750B2 (en) * 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
US8541646B2 (en) 2009-10-06 2013-09-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
ES2741649T3 (es) 2011-10-28 2020-02-11 Regeneron Pharma Ratones con complejo mayor de histocompatibilidad modificado genéticamente
PL2818478T3 (pl) 2011-10-28 2017-09-29 Regeneron Pharmaceuticals, Inc. Humanizowane il-6 i receptor il-6
RS63220B1 (sr) 2011-10-28 2022-06-30 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
EP2644027A1 (en) * 2012-03-26 2013-10-02 Institut Pasteur Transgenic immunodefficient mouse expressing human SIRPalpha.
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
IN2015DN02032A (enExample) 2012-09-07 2015-08-14 Univ Yale
ES2884598T3 (es) * 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
RU2015122228A (ru) * 2012-12-12 2017-01-19 Васкулокс Инк. Терапевтические антитела к CD47
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
CA2900824A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
MX368931B (es) 2013-09-23 2019-10-22 Regeneron Pharma Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.
AU2014337526B2 (en) 2013-10-15 2020-09-10 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
US20150143558A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
BR112016011004A2 (pt) 2013-11-19 2017-12-05 Regeneron Pharma animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
RU2700484C2 (ru) 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
NO2785538T3 (enExample) 2014-05-07 2018-08-04
PT3482629T (pt) 2014-05-19 2021-02-18 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
EP3683238A1 (en) 2014-06-19 2020-07-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
KR102659123B1 (ko) 2014-11-24 2024-04-22 리제너론 파마슈티칼스 인코포레이티드 인간화 cd3 복합체를 발현하는 비인간 동물
FI3850946T3 (fi) 2014-12-05 2023-12-28 Regeneron Pharma Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni

Also Published As

Publication number Publication date
DK3466255T3 (da) 2021-05-03
PL3466255T3 (pl) 2021-08-09
SI3850946T1 (sl) 2024-02-29
ES2716735T3 (es) 2019-06-14
LT3850946T (lt) 2024-01-10
JP2020168016A (ja) 2020-10-15
EP3466255A1 (en) 2019-04-10
AR102888A1 (es) 2017-03-29
US10015953B2 (en) 2018-07-10
DK3850946T5 (da) 2024-08-19
SG11201703463WA (en) 2017-05-30
NZ731471A (en) 2021-12-24
US20180249689A1 (en) 2018-09-06
IL286403A (en) 2021-10-31
EP3850946B1 (en) 2023-09-27
IL252019A0 (en) 2017-06-29
PL3086637T3 (pl) 2019-09-30
SMT202300482T1 (it) 2024-01-10
JP6730277B2 (ja) 2020-07-29
EP3086637A1 (en) 2016-11-02
TR201903891T4 (tr) 2019-04-22
NZ769992A (en) 2024-11-29
SI3466255T1 (sl) 2021-07-30
HUE043132T2 (hu) 2019-07-29
HRP20190634T1 (hr) 2019-08-09
EP4296278A2 (en) 2023-12-27
PT3086637T (pt) 2019-03-26
KR102313073B1 (ko) 2021-10-18
LT3466255T (lt) 2021-05-25
ES2969389T3 (es) 2024-05-17
CA2967834C (en) 2024-01-16
LT3086637T (lt) 2019-04-10
CA2967834A1 (en) 2016-06-09
AU2022203787B2 (en) 2025-01-30
SMT201900178T1 (it) 2019-05-10
PL3850946T3 (pl) 2024-03-11
CN112342197B (zh) 2025-02-18
KR20170098800A (ko) 2017-08-30
HRP20210662T1 (hr) 2021-05-28
SI3086637T1 (sl) 2019-04-30
AU2022203787A1 (en) 2022-06-23
HK1225912A1 (en) 2017-09-22
EP3466255B1 (en) 2021-02-17
EP4296278A3 (en) 2024-03-27
KR20210127773A (ko) 2021-10-22
US20160157470A1 (en) 2016-06-09
RU2728412C2 (ru) 2020-07-29
RS58536B1 (sr) 2019-04-30
RS61774B1 (sr) 2021-05-31
IL252019B (en) 2021-10-31
US20210161112A1 (en) 2021-06-03
US10939673B2 (en) 2021-03-09
MX2017007293A (es) 2018-03-12
SG10202103050YA (en) 2021-05-28
DK3850946T3 (da) 2024-01-08
KR102617691B1 (ko) 2023-12-27
JP2018500012A (ja) 2018-01-11
RS64989B1 (sr) 2024-01-31
CY1124089T1 (el) 2022-05-27
CN107205368B (zh) 2020-11-17
IL286403B1 (en) 2023-06-01
RU2017123357A3 (enExample) 2019-06-03
BR112017010490A2 (pt) 2018-04-03
EP3850946A1 (en) 2021-07-21
HRP20231707T1 (hr) 2024-03-15
PT3466255T (pt) 2021-05-10
US12389889B2 (en) 2025-08-19
EP3086637B1 (en) 2019-01-02
AU2015355328A1 (en) 2017-05-18
ES2870462T3 (es) 2021-10-27
HUE054661T2 (hu) 2021-09-28
US20160345549A1 (en) 2016-12-01
KR102508175B1 (ko) 2023-03-09
US11910788B2 (en) 2024-02-27
CN107205368A (zh) 2017-09-26
RU2017123357A (ru) 2019-01-09
CY1121547T1 (el) 2020-05-29
TWI681053B (zh) 2020-01-01
US20240138384A1 (en) 2024-05-02
JP7089554B2 (ja) 2022-06-22
SMT202100281T1 (it) 2021-07-12
DK3086637T3 (en) 2019-04-08
KR20230038599A (ko) 2023-03-20
TW201629210A (zh) 2016-08-16
CN112342197A (zh) 2021-02-09
PT3850946T (pt) 2024-01-02
AU2015355328B2 (en) 2022-03-10
HUE064960T2 (hu) 2024-04-28
IL286403B2 (en) 2023-10-01
WO2016089692A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
HRP20231707T1 (hr) Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47
FI3434101T3 (fi) Ei-ihmiseläimiä, joissa on humanisoitu signaalinsäätelyproteiinigeeni
JP7669113B2 (ja) トランスフェリン受容体トランスジェニックモデル
Encalada et al. Stable kinesin and dynein assemblies drive the axonal transport of mammalian prion protein vesicles
FI3808775T3 (fi) Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusteri 274 -geeni
Schramm et al. A novel mouse synaptonemal complex protein is essential for loading of central element proteins, recombination, and fertility
RU2016123708A (ru) Отличные от человека животные, содержащие гуманизированный ген фактора активации в-клеток
RU2016123135A (ru) Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
JP2015523863A5 (enExample)
RU2016143036A (ru) Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
Mergy et al. Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder
JP2013529181A5 (enExample)
IL319209A (en) Non-human animals containing a humanized ASGR1 locus
CN104131036A (zh) 条件型伊维菌素受体ivmr转基因小鼠模型的构建方法及应用
RU2023100305A (ru) ЖИВОТНЫЕ С ГУМАНИЗИРОВАННЫМИ IL-4 И IL-4Rα
Contreras Cornejo et al. Design and construction of a polypeptide with immunogenic potential from suppressor of hairless binding domain from Drosophila melanogaster hairless protein
RU2019131253A (ru) ЖИВОТНЫЕ С ГУМАНИЗИРОВАННЫМИ IL-4 И IL-4Rα
NZ724056A (en) Genetic markers and uses therefor
RU2020113566A (ru) НЕ ЯВЛЯЮЩИЕСЯ ЧЕЛОВЕКОМ ЖИВОТНЫЕ, СОДЕРЖАЩИЕ ГУМАНИЗИРОВАННЫЙ ЛОКУС TrkB
NZ724061A (en) Genetic markers and uses therefor
NZ724056B2 (en) Genetic markers and uses therefor
NZ765428B2 (en) Non-human animals having a humanized programmed cell death 1 gene